id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-261380-xms5su6w	Rahmani, Hamid	Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial	2020-08-24		.txt	text/plain	2770	170	51	Among an open-label, randomized clinical trial, adult patients (≥ 18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group. According to the presence of this evidence, IFN β was considered as a promising option for the treatment of In this open-label, randomized clinical trial, efficacy and safety of IFN β-1b in the treatment of patients with severe CoVID-19 were assessed. This open-label, randomized clinical trial was designed to evaluate the efficacy and safety of IFN β-1b in the treatment of patients with CoVID19 Adult patients (≥ 18 years old) with positive PCR and clinical symptoms/signs of pneumonia (including dyspnea, cough and fever), peripheral oxygen saturation (SPO 2 ) ≤ 93 % in ambient air or arterial oxygen partial pressure to fractional inspired oxygen (PaO 2 /FiO 2 ) < 300 or SPO 2 /FiO 2 < 315 and lung involvement in chest imaging were included.	./cache/cord-261380-xms5su6w.txt	./txt/cord-261380-xms5su6w.txt